Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

1.770 -0.090 (-4.84%)
Streaming Delayed Price Updated: 1:27 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Recap: Repare Therapeutics Q4 Earnings
 
Via Benzinga
Recap: Repare Therapeutics Q3 Earnings
 
Via Benzinga
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
This small-cap biotech stock holds enormous growth potential. 
Via The Motley Fool
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
From Kirby McInerney LLP
Via Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
From Repare Therapeutics Inc.
Via Business Wire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved. 
Via Benzinga
Repare Therapeutics to Regain Global Rights to Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
These Biotech Stocks Could Double Your Money, According To Analysts
 
Via Benzinga
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
From Repare Therapeutics Inc.
Via Business Wire
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... 
Via Benzinga
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.